newsfilter
← Latest News
GlobeNewswire·

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares

MDWD
  • MediWound closed a bought deal offering of 1,380,000 ordinary shares, including 180,000 shares from the full exercise of the underwriter's option.
  • The offering price was set at $12.50 per ordinary share.
  • Gross proceeds totaled $17.25 million before deducting underwriting discounts, commissions, and offering expenses.
  • H.C. Wainwright & Co. served as the sole book-running manager for the transaction.
  • MediWound plans to use the net proceeds for working capital and general corporate purposes.
  • The shares were offered under a shelf registration statement on Form F-3 originally filed with the SEC on March 19, 2025.
  • MediWound is a global leader in enzymatic therapeutics with the FDA-approved product NexoBrid for thermal burn eschar removal.
  • The company is developing EscharEx, an investigational therapy for chronic wound debridement.